MEN-10755. Menarini
1University of Texas MD Anderson Cancer Center, Department of Pharmacy, 1515 Holcombe Boulevard, Houston, TX 77030, USA. kljones@mdanderson.org
Current Opinion in Investigational Drugs (London, England : 2000)
|February 7, 2004
Abstract:
Menarini is developing the anthracycline aminodisaccharide MEN-10755 for the potential treatment of solid tumors. Six phase II trials began in 2000 to verify the therapeutic activity of the drug in a variety of tumors, including sarcoma and those of the ovary, breast, prostate and lung.
Insights
Menarini is investigating MEN-10755, an anthracycline aminodisaccharide, for solid tumor treatment. Phase II trials are assessing its efficacy across various cancers, including lung, breast, and ovarian tumors.
Area of Science:
- Oncology
- Pharmacology
Background:
- Menarini is developing MEN-10755, a novel anthracycline aminodisaccharide.
- This compound shows potential for treating various solid tumors.
Purpose of the Study:
- To evaluate the therapeutic activity of MEN-10755.
- To assess the drug's efficacy in patients with sarcoma, ovarian, breast, prostate, and lung cancers.
Main Methods:
- Six Phase II clinical trials were initiated in 2000.
- Trials focus on verifying the anticancer effects of MEN-10755.
Main Results:
- Data from Phase II trials are pending or under analysis.
- Efficacy and safety profiles are being determined for specific tumor types.
Conclusions:
- The ongoing trials will determine the clinical utility of MEN-10755.
- Results will inform potential future development for solid tumor treatment.
